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Introduksjon: Liposomer er ofte kjent for å frakte legemiddel rundt i kroppen. De blir anvendt 
på grunn av deres egenskaper til å løse opp tungt løselige legemidler, forminsker bivirkninger 
ved blant annet kreft behandlinger og øker legemidlers levetid/terapeutisk effekt i kroppen før 
de blir eliminert. Første gangen liposomer ble nevnt var for mer enn 60 år siden. Det har tidlig 
vært diskutert at disse liposomene kan skrumpe eller svelle på grunn av miljøforandringer. Det 
er ikke før i de siste årene at dette fenomenet har blitt studert i større omfang, og nå er det blitt 
påvist at størrelsen på liposomer blir påvirket av osmotisk trykk.  
Mål: Målet med oppgaven var å se hvordan fosfatbuffere av ulik tonisitet kunne forandre 
frigjøringsprofilen av to lipofile legemidler fra liposomer besående av ett dobbelt lag av lipid 
(LUVs).  
Metoder: LUVs ble tillaget ved å fordampe av løsemiddelet til en fosfatbuffer-lipid-
legemiddelløsemiddel-løsning. Liposomene ble deretter ekstrudert til ønsket størrelse og 
karakterisert ut ifra størrelse, størrelses distribusjon, overflatespenning og mengde inkorporert 
legemiddel i LUVs. For å forstå hvordan tonisitet påvirket størrelsen til liposomer, ble det ytre 
miljøet rundt LUVs forandret, og størrelse og størrelses distribusjon ble målt i isotont, hypertont 
og hypotont miljø. Permeabiliteten til hydrokortison og metylprednisolon fra løsninger eller 
LUVs ble studert ved hjelp av Franz celler igjennom en cellulose membran. I tillegg ble 
permeabiliteten av hydrokortison også studert igjennom en kunstig biologisk barriere, kalt 
Permeapad®. 
Resultater og konklusjon: Vi observerte i denne oppgaven at LUVs skrumpet og svellet da 
tonisiteten i det ytre miljøet rundt liposomene forandret seg. Videre ble det observert at 
liposomene hadde en lettere tendens til å skrumpe enn å svelle. Vi kunne også observere at 
permeabiliteten til legemiddel (som var inkorporert i LUVs) igjennom cellulose membraner 
forandret seg dersom tonisiteten forandres. Det ble funnet signifikant lavere permeabilitet for 
både hydrokortison og metylprednisolon med et hypertont ytre miljø, men ingen signifikant 
forskjell i hypotont ytre miljø. Permeabilitetsstudiene gjennomført med Permeapad® fant en 
signifikant høyere permeabilitet av hydrokortison da det ytre miljøet ble forandret til et mer 
hypotont miljø. 
Stikkord: Liposom, LUVs, hydrokortison, metylprednisolon, osmose, osmotisk trykk, tonisitet, 







Introduction: Liposomes as drug delivery systems has been widely studied as a way to 
solubilize poorly soluble drugs, reduce side effects of chemotherapeutics and increase 
circulation time in vivo. Since the first descriptions of liposomes over 60 years ago, they have 
shown tendencies to shrink and swell when the external environment of the liposomes is altered. 
This phenomenon has been studied in recent years and it is now known that liposomes’ shape 
is affected by osmotic pressure. 
Aim: The aim of this thesis was to clarify if changing the tonicity (i.e. concentration of solutes) 
outside of large unilamellar vesicles (LUVs) would affect the release of lipophilic drugs from 
them. 
Methods: LUVs were made by evaporating the solvent from a solution consisting of lipid, drug 
and solvents in phosphate buffered saline (PBS), and subsequently extruded to the desired sizes. 
The LUVs were characterized in terms of average diameter, size distribution, surface charge 
and percentage of drug entrapped inside the LUVs. To understand how tonicity affects the size 
of vesicles, the external environment of the LUVs was changed, and the size distributions of 
the LUVs were measured over time. The permeation properties of hydrocortisone and 
methylprednisolone were studied using Franz cells setup at different osmotic pressures using 
cellulose hydrate membranes or Permeapad® biomimetic barrier for both drug suspensions and 
drug-liposomal dispersions. 
Results and conclusion: We demonstrated that the LUVs shrank and swelled when the tonicity 
of the external environment was altered. We also demonstrated that the permeability of drugs 
(incorporated into LUVs) through cellulose hydrate membranes were highly affected by 
changes in tonicity. A significantly lower permeability for both hydrocortisone and 
methylprednisolone from the liposomal formulation in hypertonic external environment was 
measured, whereas no significant changes were found for the hypotonic external environment. 
The permeability studies on hydrocortisone incorporated LUVs employing the, Permeapad® 
showed a significantly higher permeability when changing the tonicity to hypotonic 
environment. 
Keywords: Liposomes, large unilamellar vesicles, LUVs, hydrocortisone, methylprednisolone, 
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1 Introduction  
1.1 Liposomes 
1.1.1 What are liposomes? 
Liposomes are a type of nano drug carrier which consists of spherical vesicles composed of 
phospholipid bilayers, typically dispersed in an aqueous medium. These vesicles can vary 
greatly in size and have one or more bilayer conformations in the barrier of the vesicles. 
Liposomal bilayers are primarily comprised of biocompatible constituents such as natural 
phospholipids, synthetic phospholipids, cholesterol and/or polymers (Alavi et al., 2017; Xu et 
al., 2016). Phospholipids used in liposomal formulations can be natural derivatives such as 
phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine and phosphatidylinositol. 
These are usually derived from a number of different sources such as chicken eggs, soy and 
bovine milk. Some vesicles can also be made by synthetic phospholipids such as dipalmitoyl 
phosphatidylglycerol, distearoyl phosphatidylcholine among others. There are also other 
constituents which can be incorporated within the phospholipid bilayers such as cholesterol 
which can be used to stabilize and increase the rigidity of phospholipid bilayers (Alavi et al., 
2017; De Gier et al., 1968; Li et al., 2015). Mucoadhesiveness of lipid bilayers can be increased 
with the addition of chitosan, whereas, increases in vivo circulation time of liposomal 
formulations can be achieved by PEGylation or addition of ligands for ligand based targeting 
(Allen and Cullis, 2013; Anwekar et al., 2011; Li et al., 2015).Liposomal formulations are 
appealing for drug delivery for different reasons. Liposomes are very efficient as solubilizing 
agents for poorly soluble drugs, inducing a drastic increase of apparent aqueous solubility for 
many poorly soluble drugs (di Cagno et al., 2011; di Cagno and Luppi, 2013; Yang et al., 2007). 
It has also been shown that liposomal formulations can reduce side effects of chemotherapeutic 
agents (Boulikas, 2004). Liposomal formulations can have longer circulation time in vivo and 
increase selectivity for particular areas of the body (Allen and Cullis, 2013; Brandl, 2001). 
When it comes to disadvantages of liposomal drug delivery systems there are higher production 
costs, problems with upscaling of preparation methods, time consuming preparation methods, 
oxidation and hydrolysis of the phospholipids and shorter half-life of the formulations in vivo 
(Alavi et al., 2017; Anwekar et al., 2011; Brandl, 2001; Samad et al., 2007). 
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Figure 1: Graphic representation of a phospholipid-based liposome with hydrophilic and lipophilic drug 
incorporated into the aqueous core and lipid bilayer. 
A variety of lipophilic, hydrophilic and amphiphilic drugs can be incorporated into liposomes. 
Hydrophilic drug would reside inside the aqueous core, hydrophobic drugs will be incorporated 
inside the hydrophobic region of the lipid bilayer, amphiphilic compounds will reside both 
inside the aqueous core and inside the lipid barrier (Brandl, 2001; Hupfeld et al., 2006). The 
partitioning coefficients of drugs (logP) which indicates the ratio of drug in octanol/water 
mixture can be employed as a way to predict where drugs would be located into liposomes 
(inner core of bilayer). A high logP would mean that the drug is more lipophilic, and that drug 
is primarily incorporated into the lipid bilayer as opposed to the aqueous medium of the inner 
core. A logP value closer to zero could mean that the drug is of neutral partitioning properties 
and could be partly inside the aqueous core and partly inside the lipophilic area of the liposomal 
bilayer (Benet et al., 2011; Leo et al., 1971).  
1.1.2 Size and shape of liposomes 
Liposomal sizes generally range from 20 nm to several µm in diameter. Size plays a significant 
role in the biodistribution and circulation time of liposomal formulations in vivo as well as in 
vitro characteristics like aggregation of the individual liposomes, sedimentation and the amount 
of drug that can be entrapped inside the formulation (Hupfeld et al., 2006; Samad et al., 2007). 
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Liposomes are generally classified according their size and level of lamellarity as: 
- Small unilamellar vesicles (SUVs)have a size range from about of 20-100 nm  
- Medium sized unilamellar vesicles (MUVs) are >100 nm in diameter 
- Large unilamellar vesicles (LUVs) have a size of >100 nm in diameter  
- Giant unilamellar vesicles (GUVs) are > 1µm in diameter 
- Multilamellar large vesicles (MLVs) size >500 nm, have between 5 and 25 lipid bilayers. 
- Multilamellar vesicles (MV) size > 1µm in diameter and have multiple vesicles inside a 
lipid bilayer. 
Photon correlation spectroscopy (PCS) or dynamic light scattering is a common approach to 
simultaneously measure vesicle sizes and polydispersity (size distribution) of liposomal 
dispersions. PCS works by scattering monochromatic light through a colloidal dispersion of 
particles. The light will then change the wavelength in correlation to the movement of the 
particles (Brownian movement) in the dispersion and size of the nanoparticles can be 
extrapolated from their movement (Kumar et al., 2016). The size and size distribution affects 
the amount of drug that is entrapped inside a formulation, aggregation and sedimentation of the 
liposomes. (Anwekar et al., 2011; Brandl et al., 1998; Hupfeld et al., 2006) 
1.1.3 Liposomal preparation methods 
Many different methods have been designed for preparing liposomal formulations. The first 
method for making liposomes introduced was the “thin film method” by Bangham et al. (1965). 
It is the most common method utilized for liposomal preparations and it is based on the 
reconstitution of a thin film of lipids made by vacuum evaporation of solvents with aqueous 
media (Bangham et al., 1965). Another method that can be used is the “ether vaporization 
method”, where a lipid solution in highly volatile organic solvent (ethanol or ether) is injected 
into an aqueous medium through a fine needle to make liposomes (Samad et al., 2007). An 
alternative method widely employed is the “reverse phase evaporation method”. In this 
procedure, rotary evaporation is employed in order to evaporate solvents from a lipid/solvent 
mixture. The concentrated mixture is then rehydrated using a buffer solution to create liposomes 
(Samad et al., 2007; Szoka and Papahadjopoulos, 1978). The preparation method used in this 
thesis was first described by Moscho et al. (1996), it is a variation of the “reverse-phase 
evaporation method”. In short, chloroform/lipid solution and methanol are evaporated through 
an aqueous buffer solution by the means of rotary evaporation to form giant unilamellar vesicles 
(Moscho et al., 1996).  
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1.1.4 Methods for size reduction of liposomes 
Liposomal sizes could be reduced by a number of different methods, one of the most common 
ones is the extrusion of liposomes through polycarbonate membranes. In in short; an aqueous 
dispersion containing liposomes are extruded through polycarbonate membranes with fixed 
sized pores, some of the pore sizes available include 1.0, 0.8, 0.6, 0.4 and 0.2 µm. This method 
has been shown to give liposomal dispersions with a low polydispersity and an homogenous 
size distribution (Brandl, 2001; Olson et al., 1979). The use of ultrasounds has been proven to 
be an efficient method in order to reduce vesicle sizes quite efficiently (>200 nm in diameter). 
The liposomal dispersion is sonicated using a probe for a set amount of time. This method 
works by generating shockwaves that form imploding gas/steam-bubbles. Upon implosion 
cavities are formed in the dispersions which breaks up the liposomes and makes them 
reconstitute into a smaller size (Brandl, 2001; Hupfeld et al., 2006). An alternative technique 
for reducing the size of liposomal vesicles is the use of high pressure homogenizers, using the 
principle of cavitation same as the ultrasonication method. Here the liposomal dispersions are 
accelerated through a narrow gap which breaks up the liposomal vesicles and makes them 
reform into smaller vesicles. Microfluidizers use high pressure in combination with the 
principle of forming and imploding gas/steam-bubbles. The liposomal formulation is pressured 
through two micro channels which forces the liposomes to break up and reform in smaller sizes 
(Brandl, 2001). 
1.1.5 Zeta potential 
Surface charge of liposomes is generally quantified by the parameter zeta potential (ZP), This 
measurement of the electric potential (mV) is made on what is called the “slipping plane” in a 
colloidal dispersion. The “slipping plane” is the boundary between the stationary layer of 
charged particles around the dispersed particles and particles moving freely in the dispersion 
(Attard et al., 2000; Coday et al., 2015). ZP is important because charge in liposomal 
membranes either positive or negative can increase the electrostatic repulsion between the 
liposomes if they carry the same net charge, which could give a liposomal formulation better 
stability when it comes to aggregation and sedimentation (Narenji et al., 2016). Electrostatic 
repulsion between liposomes which carry a net charge have been shown to reduce size and 
lamellarity of liposomes (Talsma et al., 1992). 
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1.2 Osmosis and osmotic pressure 
Osmosis is a natural phenomenon associated to the movement of water from a solution of low 
concentration through a semipermeable membrane to a solution of high concentration. This 
movement of water is induced by differences in chemical activity (i.e. concentration gradient) 
of solutes between two sides of a semipermeable membrane. Water molecules move from the 
side of the membrane with the lowest solute concentration (hypotonic environment) to the side 
with higher solute concentration (hypertonic environment) in order to equalize the chemical 
activity and therefore the concentration gradient. (Brandl et al., 2008; Rasouli, 2016; Sinko, 
2006) The phospholipid bilayer of liposomes is semipermeable, this means that osmosis can 
occur either from the inside of the liposome to the outside (efflux) or from the outside to the 
inside (influx) (Ohno et al., 2009; Paula et al., 1996; Rasouli, 2016). Osmotic pressure is a 
colligative property of solutions and is defined as the difference in pressure between a solution 
and pure liquid solvent across a membrane. It is the driving force of osmosis and is the force of 
water diffusing through a semipermeable membrane when trying to equalize the chemical 
activity of a system over a surface. J. Van ’t Hoff were the first person to propose a law to 
calculate osmotic pressure. This is represented as Equation 1: 
Equation 1 p𝑉 = 𝑛𝑅𝑇 
Where p is the osmotic pressure, V the volume of the solution, n is moles of solutes, R is the 
gas constant and T is the absolute temperature.  
The first van ‘t Hoff equation did however not take into account that molecules can be divided 
into sub particles in the case of e.g. ions which would give a higher osmotic pressure than non-
ionizing solutes. The new equation given by van ‘t Hoff took in to account the van ‘t Hoff factor 
i, this is described as the number of electrolytes (ions) and nonelectrolytes yielded by 
dissociation of a molecule in a medium. Described as Equation 2: 
Equation 2 p	 = 𝑖𝑅𝑇𝑐, 
where p is the osmotic pressure, 𝑖 the number of ions a molecule dissociates into, R is the gas 
constant, t is the absolute temperature and c is the concentration of the solution (Sinko, 2006). 
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Osmolality is defined as mole of a solute dissolved in 1 kg of solvent and is measured in Osm/kg 
H2O. The equation used for calculating the relative osmotic pressure (πrel) between buffers of 
different osmolality is a variation of the van ’t Hoff equation for calculation osmotic pressure 
(Koeppen and Stanton, 2013; Sinko, 2006) this is represented as Equation 3: 
Equation 3 p)*+ = 𝑅 ∗ 𝑇 ∗ (𝑂𝑠𝑚(123) −	𝑂𝑠𝑚(67))	 
Where πrel is the relative osmotic pressure, R is the gas constant, T is the absolute temperature 
and Osm(out) – Osm(in) are the difference between external and internal osmolality (mOsm) (Wu 
et al., 2017). 
1.3 Liposomes and tonicity 
Liposomes can shrink and swell due to altered tonicity. This phenomenon has been studied over 
the years and it has been showed that it is possible to induce changes in the size of liposomes 
by changing the tonicity on the outside of the liposomes in a dispersion. This happens as a result 
of water movement induced by changing the tonicity of the dispersing medium from an isotonic 
environment to either a hypertonic- or a hypotonic environment. The osmotic pressure caused 
by changing the tonicity can draw water out of the aqueous core of the liposome if the external 
environment is hypertonic, causing the liposomal bilayer to contract and shrink. Osmotic 
pressure can also draw water into the core when the external environment of the liposome is 
hypotonic, causing the liposomal bilayer to expand (Ahumada et al., 2015; Alam Shibly et al., 
2016; Bangham et al., 1967; Biondi et al., 1991; Hallett et al., 1993; Mui et al., 1993; Polozov 
et al., 2001; Rutkowski et al., 1991; Sun et al., 1986). These findings are corroborated by a 
recent study done employing the liposomal formulation and phosphate buffered solutions which 
is going to be used in this study (Wu et al., 2017). Sabín et al. (2006) found that increasing the 
cationic (e.g. Na+) concentration on the outside of a liposomal membrane, an osmotic force 
would be created driving water out through the liposomal membrane and create shrinkage of 
the liposomes. The authors suspected this was due to the low permeability of cations through 
the liposomal bilayer (Sabín et al., 2006). However, membrane thickness and size of the 
lipophilic region of the lipid bilayer of liposomes seem to have an effect on the permeability of 
cations as well (Paula et al., 1996). 
1.4 Drug permeation across barriers 
Passive diffusion is a process in which drug moves from areas of high concentration to areas of 
lower concentration spontaneously to equalize the concentration of a solution.  
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This allows molecules to pass through a membrane by following the concentration gradient of 
the drug when it moves from a place of high concentration to a place of lower concentration 
(Brandl et al., 2008; Sinko, 2006). This movement of molecules over a membrane can be 
measured for instance by a Franz diffusion cell, where a donor chamber (place of high drug 
concentration) and an acceptor chamber (place of low drug concentration) are separated by a 
membrane in which the drug molecule can diffuse through. This movement of drug molecules 
from the donor chamber to the acceptor chamber per time unit, times the inverse of the 
membrane area (in contact with the solutions) is called the flux. The flux (𝑗) of a drug can be 
calculated from the linearly part of a curve where the cumulative amount of diffused drug is 







Where	𝑗 represents the flux, Dm/Dt is the mass transfer (number of drug particles diffusing 
through a membrane per time unit) and A is the surface area of the diffusion membrane.  
The apparent permeability (Papp) of a drug through a membrane normalizes the flux over the 





𝑗 represents the flux and c the concentration of solubilized drug in the donor compartment. 
 
1.5 Permeapad® barrier  
The Permeapad® biomimetic barrier was first described by di Cagno et al. (2015) as a method 
for screening the permeability of drugs through artificial membranes. There are several different 
types of in vitro drug release assays to experimentally determine how permeable a drug can be 
in vivo. Some of the methods include the Parallel Artificial Membrane Permeability Assay 
(PAMPA), the Phospholipid Vesicle-based Permeation Assay (PVPA). These assays employ 
phospholipids either dissolved in solvent and dried (PAMPA) or as a phospholipid vesicle-
based layer (PVPA) on a filter support (Flaten et al., 2006; Kansy et al., 1998). Another in vitro 
method for determining in vivo drug release is the caco-2 model which employs grown cell 
cultures in a monolayer formation on top of polycarbonate membranes (Hidalgo et al., 1989). 
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The Permeapad® barrier is comprised of a thin layer of lipid in between two supporting layers. 
This model works on the principle of hydrating the lipids between the supporting layers to make 
a spheroid like structure with lipid bilayers running through it, mimicking a cell membrane 
(Berben et al., 2018; di Cagno et al., 2015; di Cagno and Bauer-Brandl, 2016). The background 
for developing the Permeapad® was to find a fast, cost effective and reliable method for 
determining permeability of drugs through barriers resembling in vivo biological barriers. The 
Permeapad® have been shown to give similar permeability estimates when compared with 
previously established methods of in vitro permeability assessment such as the PVPA and 
PAMPA Assays. The Permeapad® has been found compatible with a variety of different 
surfactants, solvents and biomimetic mediums as well as being resistant to fluctuations in pH 
and give reliable results at different pH levels (Bibi et al., 2015; di Cagno et al., 2015). For 
these reasons have the Permeapad® been chosen as the assay used in this work. 
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2 Aim of the study 
The aim of this thesis was to clarify if changing the tonicity (i.e. concentration of solutes) on 
the outside of large unilamellar vesicles (LUVs) would affect the release of lipophilic drugs 
from them.  
3 Drugs, materials, equipment and software 
3.1 Drugs 
Table 1: Molecular formula, molecular weight (MW), partition coefficient (LogP), ionization constant (pKa) and 
measured solubility for the investigated drugs. 
 Formula MW (g/mole) Log P pKa 
Solubility 
(mg/mL) 
Hydrocortisone C21H30O5a 362.46a 1.6c 12.48e 0.420c 
Methylprednisolone C22H30O5b 374.47 b 1.80d 12.46f 0.323c 
aSigma-Aldrich, (n.d.) 
bSigma-Aldrich, (n.d.) 
cBenet et al. (2011) 
dGrabowski et al. (2010) 
eDursch et al. (2014) 
fCalculated value using Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 
1994-2017 ACD/Labs) 
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3.2 Materials and chemicals 
Table 2: Materials and chemicals used in the studies and their producers. 
Materials Producer 
Acetic acid (≥99.8%) Sigma-Aldrich Chemie GmbH (Steinheim, Germany) 
Cellulose hydrate membrane 
(Visking dialysis tubing, MWCO 12-14 kDa) 
Medicell Membranes Ltd 
(London, UK) 
Chloroform (≥99%) Sigma-Aldrich Chemie GmbH (Steinheim, Germany) 
Hydrocortisone Sigma-Aldrich Chemie GmbH (Steinheim, Germany) 
Lipoid S100  
(soy phosphatidylcholine S100, >94%) 
Lipoid GmbH 
(Ludwigshafen, Germany) 
Methanol (≥99.9%) Sigma-Aldrich Chemie GmbH (Steinheim, Germany) 
Methylprednisolone Sigma-Aldrich Chemie GmbH (Steinheim, Germany) 
Permeapadâ barrier InnoME GmbH (Espelkamp, Germany) 
Sodium chloride (≥99.5%) Sigma-Aldrich Chemie GmbH (Steinheim, Germany) 
Sodium hydroxide (≥98%) Sigma-Aldrich Chemie GmbH (Steinheim, Germany) 
Sodium phosphate dibasic dihydrate 
(98.5-101.0%) 
Sigma-Aldrich Chemie GmbH 
(Steinheim, Germany) 
Sodium phosphate monobasic monohydrate 
(≥99.0%) 
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3.3 Equipment 
Table 3: Equipment used in the studies and their producers. 
Equipment producer 
Acrodisc® Syringe filter with  
Supor® membrane (0.45 µm) 
PALL 
(New York, USA) 
Filter holder (Swinnex-25 Millipore) for 
WhatmanÒ nuclepore™ membranes 
Sigma-Aldrich Chemie GmbH 
(Steinheim, Germany) 
Folded capillary zeta cells Malvern Instruments Ltd. (Worcestershire, UK) 
Franz cell 5 mL acceptor volume 
(jacketed flat ground; pinch clamp and stir bar 
with a Standard diffusional area of 0.64 cm2), 
PermeGear Inc. 
(Pennsylvania, USA) 
Franz cell 6 station stirrer (V6-CA) PermeGear Inc. (Pennsylvania, USA) 
Milli -Q® gradient, with  
MillipakÒ M 0.22µm filter 
Millipore Corporation 
(Damstadt, Germany) 
Osmometer (Semi-Micro k-7400) Knauer (Berlin, Germany) 
pH-meter (SensION™ + PH 31) Hach (Barcelona, Spain) 








Rotavapor (Büchi R-124) Büchi Labortechnik AG (Flawil, Switzerland). 
Shaking water bath (GFL 1086) Gemini BV (Apeldoorn, Netherlands) 
Square polystyrene cuvettes (12 mm) Malvern Instruments Ltd. (Worcestershire, UK) 
Sterile syringe filter with polyetersulfone 
(PES) membrane (0.2 µm) 
VWR International (Pennsylvania, 
USA) 
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Ultracentrifuge 
(Beckman model L8-70 M with SW 60 Ti rotor) 
Beckman Instruments (California, 
USA) 




UV plate (CostarÒ 96-well) Corning (New York, USA) 
Vacuum pump (Büchi V-500) Büchi Labortechnik AG (Flawil, Switzerland). 
Water bath (Büchi B-480) Büchi Labortechnik AG (Flawil, Switzerland). 
Waters 2690 separation module Waters Corporaton (Milford,USA) 
Waters 996 Photodiode array UV-vis detector Waters Corporaton (Milford,USA) 
Whatman® Nuclepore™ Track-Etched 
Membranes (0.4 µm pore size) 
Sigma-Aldrich Chemie GmbH 
(Steinheim, Germany) 
Whatman® Nuclepore™ Track-Etched 
Membranes (0.8 µm pore size) 
Sigma-Aldrich Chemie GmbH 
(Steinheim, Germany) 
XTerraÔ RP 185 µm 3.9x150mm colum Waters Corporaton (Milford,USA) 
Zetasizer Nano Zen 2600 Malvern Instruments Ltd. (Worcestershire, UK) 
 
3.4 Computer software 
Table 4: Software used in the studies together with versions of the software and producers. 
Name of software Version of software Producer 
Millennium32 v3.20 Waters Corporaton (Milford,USA) 
SoftMax® Pro v5 Molecular devices (California, USA) 
Zetasizer Software v7.11 Malvern Instruments Ltd. (Worcestershire, UK) 
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4 Methods 
4.1 Phosphate buffered saline (PBS) preparation 
Phosphate buffered saline with an osmolality of 300 mOsm (PBS300) was prepared following 
a method previously described Wu et al., (2017). In short, 22.5 g sodium phosphate monobasic 
monohydrate, 36.8 g sodium phosphate dibasic dihydrate, 22.9 g sodium chloride and 3.9 g 
sodium hydroxide were added to 5 L distilled water. The mixture was left stirred until the salts 
were completely dissolved. The pH of the buffer was adjusted to 7.4 (SensION™ + PH 31 pH 
meter, Hach, Barcelona, Spain) with sodium hydroxide. The tonicity was adjusted to 300 mOsm 
(Semi-Micro osmometer k-7400, Knauer, Berlin, Germany) with sodium chloride. PBS300 was 
diluted with distilled water in order to obtain two other buffer solutions (PBS190 (1.5:1 v/v), 
and PBS65 (1:4 v/v) respectively. 
4.2 Preparation of large unilamellar vesicles 
Large unilamellar vesicles were prepared following a method previously described by Wu et 
al. (2017). PBS solution (10 mL, PBS300 or PBS65) was added on top of an organic solution 
composed of drug/soy phosphatidylcholine (molar ratio 1: approx. 1.3) in CHCl3 (1 mL) on top 
of methanol (0.2 mL) in a 50 mL round bottom flask. The organic solvents were gently removed 
by rotary evaporation (40°C, 40 rpm, Büchi R-124 rotavapor, Büchi vacuum pump V-500, 
Büchi B-480 water bath, Büchi Labortechnik AG (Flawil, Switzerland). The pressure was 
carefully reduced in increments of 100 mbar to 500 mBar, and then 10 mBar increments to 100 
mBar (took approximately 20 min in total). After 90 min of evaporation at 100 mbar, giant 
unilamellar vesicles (GUVs) were formed. The GUVs were left over night at fridge temperature 
(2-8°C). 
 
Figure 3: Graphic representation of liposomal preparation of GUVs by bubbling solvents containing drug + lipid 
through a phosphate buffered saline solution. 
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Room tempered (23-25°C) liposomal dispersions were then extruded through polycarbonate 
membranes (Nuclepore™ Track-Etched membrane, Sigma-Aldrich Chemie GmbH (Steinheim, 
Germany) of pore size 0.8 µm (5 times) and 0.4 µm (10 times) using a Swinnex-25 Millipore 
filter holder (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) to reduce the liposomal 
sizes to large unilamellar vesicles (LUVs). 
4.3 Osmotic activity determination 
LUVs were exposed to different osmotic pressures in order to quantify at which extent LUVs 
sizes were affected by the exposure to different tonicities. Size analysis were performed 
employing the Zetasizer Nano Zen 2600 (Malvern industries, Worcestershire, UK). In brief, 
liposomal dispersions (500 µL) at room temperature (23-25°C) were filtered with 0.45 µm 
sterilized filter (Acrodisc® Syringe filter with Supor® membrane, PALL, New York, USA) and 
diluted 1:100 in PBS300 (alternatively, PBS65) in order to induce osmotic shock. Diluted 
LUVs were filtered through a 0.2 µm sterilized filter (Sterile syringe filter with PES membrane, 
VWR International, Pennsylvania, USA) prior to the size measurements. The experiments were 
conducted at time points: 0, 15, 30, 45 and 60 min in triplicates, each sample were measured 
thrice at each time point.  
4.4 Characterization of liposomes 
4.4.1 Liposomal size characterization 
The sizes of the extruded LUVs were measured using photon correlation spectroscopy with an 
angle of 173°, using a square polystyrene cuvette (12 mm, VWR International) together with 
the Zetasizer Nano Zen 2600 (Malvern). The LUV dispersions were diluted 1:100 (v/v) in 
buffer solution of the same tonicity as the LUVs. Thereafter, the diluted dispersions were 
filtered using a 0.2 µm sterilized filter (VWR International) prior to measurement. Experiments 
were conducted in duplicates, and each sample were measured three times. 
4.4.2 Zeta potential determination 
The surface charge of the extruded LUVs was determined by measuring the zeta potential (ZP) 
using a folded capillary zeta cell from Malvern industries with the Zetasizer Nano Zen 2600 
(Malvern) previously described by (Wu et al., 2017)The LUVs were diluted 1:20 (v/v) with 
filtered deionized water (23-25°C, 0.2 µm pore size sterile syringe filter, VWR International) 
prior to measurement. Experiments were conducted in duplicates, and each sample were 
measured three times. 
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4.4.3 Entrapment efficiency determination 
Drug entrapped inside the LUVs was quantified using a ultracentrifugation method previously 
described by Wu et al. (2017), in order to separate the entrapped drug inside the LUVs from 
unentrapped drug in the dispersion. Room tempered liposomal dispersion (23-25°C, 1 mL) 
were centrifuged for 30 mins with a speed of 38500 rpm at 10°C (g-force of 200 000) in a 
Beckman model L8-70 M ultracentrifuge with SW 60 Ti rotor, (Beckman Instruments, 
California, USA). The supernatant (with free drug) was carefully removed from the pellet 
containing the liposome-associated drug. 
In order to determine the amount of drug inside the LUVs were the vesicles destroyed with a 
50% methanol/PBS (v/v) solution. The drug concentrations were quantified using UV-visible 
spectroscopy on a clear polystyrene microplate with 96 wells (Corning, New York, USA) using 
a SpectraMAX® 190 microplate reader, with SoftMax® Pro v5 software (Molecular devices, 
California, USA). The analysis was performed at the maximum absorbance wavelength (λmax) 
of 247 nm for hydrocortisone and 248 nm for methylprednisolone. The entrapment efficiency 
of the LUVs was calculated according to an equation described by Wu et al. (2017): 




Where Mtot represent the total amount of drug in the liposomal dispersion, Mfree the amount of 
unentrapped drug after ultracentrifugation. Experiments were performed in three parallels. 
4.5 Standard curves 
The standard curves for hydrocortisone (HC) were made form a 552 µM stock solution in 
PBS300 or PBS65. The stock solution was then diluted with pure PBS of same osmolality or 
50% methanol/PBS (v/v) to make standard solutions with concentrations of 0, 5, 10, 20, 40, 60, 
80 and 100 µM. For methylprednisolone (MP), 185 µM stock solution was prepared in 50% 
methanol/PBS300 (v/v), alternatively, PBS65 and diluted with 50% methanol/PBS to make a 
standard curve with the concentrations of 0, 1, 2.5, 5, 10, 20, 40, 60, 80 and 100 µM. 
The standard curve concentrations were quantified by multi well plates for UV-visible 
spectroscopy employing Costar® UV 96 well plate (Corning) using the SpectraMAX® 190 
microplate reader, with SoftMax® Pro v5 software (Molecular devices). The analysis was 
performed at the maximum absorbance wavelength (λmax) of 247 nm for hydrocortisone and 
248 nm for methylprednisolone.  
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4.6 Thermodynamic solubility determination 
Saturated drug solutions (suspensions) of HC and MP (1 mg/mL) were prepared in PBS300 and 
PBS65. The suspensions were frequently vortexed and left in a water bath (GLF 1086 Shaking 
water bath, Gemini BV, Apeldoorn, Netherlands) at 35°C until thermodynamic equilibrium was 
reached. The drug suspensions (1 mL) were filtered using a 0.2 µm sterile syringe filter (VWR 
International). The concentration of the filtered solutions was quantified using UV-visible 
spectroscopy on a clear polystyrene microplate with 96 wells (Corning) using a SpectraMAX® 
190 microplate reader, with SoftMax® Pro v5 software (Molecular devices). The experiments 
were done in triplicate for each of the drug suspensions. 
4.7 Drug permeability and release studies 
4.7.1 Drug permeability study of drug solutions using cellulose hydrate barriers 
An in vitro drug permeability study was preformed using saturated drug solutions (to maintain 
sink conditions) from chapter 4.6 together with cellulose hydrate membranes. A Franz diffusion 
cell setup where employed according to a method previously described (Wu et al., 2017). 
Jacketed flat ground Franz cells with 5 mL acceptor volume and standard 0.64 cm2 diffusional 
area (PermeGear Inc., Pennsylvania, USA, USA) was used on a 6-station Franz Cell stirrer 
(PermeGear Inc., Pennsylvania, USA). This setup was connected to a Julabo 
refrigerated/heating circulator (JULABO GmbH, Seelbach, Germany). The temperature of the 
heating circulator was set to 40°C on the Julabo F12 (36°C on the Julabo 200F), to achieve a 
membrane temperature of approx. 35°C.  
The saturated drug solutions from chapter 4.6 were used as the donor and 5 mL of PBS buffer 
of the same tonicity as the drug solutions were used in the acceptor chambers. The cellulose 
hydrate membranes (dialysis tubing, MWCO 12-14 kDa, Medicell membranes Ltd., London, 
UK) were hydrated in buffer (PBS300/PBS65) according to which buffer the solutions were 
made in. The study began by adding 0.8 mL of the saturated drug solutions to the donor chamber 
of the Franz cells. The study was preformed over 4 hours with sampling (0.5 mL) from the 
acceptor chamber every 0.5 hours over a period of 4 hours. The same amount of fresh PBS of 
same osmolality was returned to the acceptor chamber after sampling in order to maintain sink 
conditions. At the end of the experiment, samples of the acceptor chamber, content of the donor 
chamber and membranes were collected for analysis.  
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The membranes were suspended in 5mL of the respective PBS buffer for 30 min to quantify 
the amount of drug left on the membranes. The drug concentration in acceptor chamber, donor 
chamber and on the membranes were quantified using UV-visible spectroscopy in the 
SpectraMAX® 190 microplate reader with SoftMax® Pro v5 software (Molecular devices) as 
previously described at the end of chapter 4.4.3.  
4.7.2 Drug release study using cellulose hydrate barriers 
An in vitro release study employing the same Franz diffusion cell setup as chapter 4.7.1 were 
performed using hydrocortisone and methylprednisolone incorporated LUVs. The liposomal 
dispersions were tested with cellulose hydrate barriers (Medicell membranes Ltd.) on the Franz 
diffusion cell setup. 
Table 5: Buffer type in the aqueous core of large unilamellar vesicles (LUVs) vs. the buffer type in the 
environment outside LUVs and calculated relative osmotic pressure (πrel) using Equation 3. 
Buffer type 
πrel (bar) 
Core of LUVs Environment outside LUVs 
PBS300 PBS65 -6 
PBS300 PBS190 -3 
PBS300 PBS300 0 
PBS65 PBS65 0 
PBS65 PBS190 3 
PBS65 PBS300 6 
 
PBS buffer (5 mL, PBS300, 190 or 65) was added to each acceptor chamber in accordance with 
Table 5 to obtain the respective osmotic pressures. Cellulose hydrate membranes (Medicell 
membranes Ltd.) were hydrated in buffer (PBS300 or PBS65) according to which buffer the 
LUVs were made in. The study began by adding 0.8 mL of LUVs (2 mM total concentration) 
to the donor chamber on the Franz cells. Sampling (0.5 mL) from the acceptor chamber every 
0.5 hours over a period of 4 hours were carried out. The same amount of fresh PBS of same 
osmolality was returned to the acceptor chamber after sampling in order to maintain sink 
conditions.  
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At the end of the experiment, samples of the acceptor chamber, content of the donor chamber 
and membranes were collected for analysis. The membranes were suspended in 5mL PBS for 
30 min to quantify amount of drug left on the membrane. The concentration of drug in acceptor 
chamber, donor chamber and on the membranes were quantified using UV-visible spectroscopy 
in the SpectraMAX® 190 microplate reader (Molecular devices) as previously described at the 
end of chapter 4.7.1. 
4.7.3 Drug permeability study of drug solutions using the Permeapad® barrier 
The Permeapad® (InnoME GmbH, Espelkamp, Germany) biomimetic barriers were employed 
in an in vitro drug permeability experiment as described in chapter 4.7.1 using suspensions of 
hydrocortisone. The Permeapad® (InnoME GmbH, Espelkamp, Germany) biomimetic barriers 
were employed as the barrier between the donor and acceptor chambers instead of the hydrated 
cellulose membranes. The buffer solutions employed were PBS300 and PBS65 which were 
used in the acceptor chambers according to Table 5 for osmotic pressures of -6, 0 and 6. This 
study was performed as previously described in chapter 4.7.1 (n=3). At the end of the study, 
samples from the donor chamber and acceptor chamber where analysed as previously described 
at the end of chapter 4.7.1. The drug left on top of and inside the Permeapad® barriers were 
analysed with high performance liquid chromatography (HPLC) The method used for 
quantifying HC along with the settings represented in Table 6 where adapted from Adi-Dako 
et al. (2017). 
Table 6: Settings for High-performance Liquid chromatography of hydrocortisone left on top of and inside the 
Permeapad® biomimetic barriers 
Parameters values 
Flowrate 1 mL/min 
Column temperature 25°C 
Sample temperature 25°C 
Injection volume 20 µL 
Runtime 5 min 
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In brief, a Waters 2960 separation module (Waters Corporation, Milford, USA) were used in 
conjuncture with an XTerraÔ RP 185 µm (3.9x150mm, Waters) separation column and a 
Waters 996 photodiode array UV-vis detector (Waters). The mobile phase used during the 
experiment were made from methanol/Milli-Q water/acetic acid with a ratio of 60/30/10 (v/v/v). 
The standard curve for the HPLC where diluted from a 0.2 mM stock solution (hydrocortisone 
dissolved in the mobile phase), to concentrations of 0, 12, 25, 50, 75, 88, 100 µM. The 
Permeapad® barriers were also suspended in the mobile phase prior to measurement. 
4.7.4 Drug release study using Permeapad® barriers  
The same in vitro release experiments as chapter 4.7.2 were conducted on hydrocortisone 
incorporated LUVs using the Permeapad® (InnoME GmbH) barriers as the membrane between 
the donor and acceptor chamber on the Franz cells. The buffer solutions employed were 
PBS300 or PBS65 which were used in the acceptor chamber. This study was performed as 
previously described in chapter 4.7.2. At the end of experiment, samples from the donor 
chamber, acceptor chamber were analysed as previously described at the end of chapter 4.7.1. 
4.8 Statistical analysis 
Student’s t-tests were employed to determine if there was a significant difference between the 
mean apparent permeability of two datasets (p≤0.05). Confidence interval (95%) was used to 
evaluate the time point a significance in drug permeability was observed between the 
environments within the same LUV formulation at different osmotic pressures. 
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5 Results 
5.1 Buffer solutions 
Tonicity and pH of the different PBS solutions employed in the experiments. Results are 
reported in Table 7: 
Table 7: Measured pH, tonicity and calculated phosphate concentration of the phosphate buffered saline (PBS) 
solutions used in the studies *(average ± SD, n=≥4). 
Buffer pH* Osmolality (mOsm)* Phosphate concentration (mM) 
PBS300 7.40 ± 0.04 300 ± 4 78 
PBS190 7.47 ± 0.04 190 ± 7 47 
PBS65 7.60 ± 0.05 65 ± 3 16 
 
5.2 Liposomal size analysis and tonicity changes 
The influence of tonicity on the sizes of LUVs was investigated by photon correlation 
spectroscopy (PCS). As shown in (Figure 4 and Figure 5), LUVs with hydrocortisone were 
exposed to isotonic, hypotonic and hypertonic environments in order to observe how the size 
distributions of the LUVs would be affected by tonicity changes. 
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Figure 4: Size and distribution changes of hydrocortisone incorporated large unilamellar vesicles (LUVs) over 1 
hour in isotonic environment (top) and when subjected to hypotonic environment (bottom). LUVs were prepared 
in phosphate buffered saline (PBS) solution of 300 mOsm and exposed to buffer with tonicity of 300 (top) or 65 
mOsm (bottom), respectively. The dotted line marks 300 nm size (n=30) 
Size distribution changes of HC-LUVs prepared in PBS300 where studied in isotonic 
environment (PBS300) and in hypotonic environment (PBS65) over a period of 1 hour (Figure 
4). When the LUV dispersions prepared in PBS300 were exposed to isotonic environment (top 
graph), one peak of high intensity was observed at around 290-300 nm. When LUVs were 
exposed to the hypotonic environment (PBS65, bottom graph) a slight decrease in peak 
intensity (from 15% to 10 %) was observed at the same dimension (300 nm, red line in Figure 
4). Moreover, the formation of peaks at the larger sizes (between 400-2000 nm range) where 
observed and a small (but noticeable) shift towards smaller size distribution was measured. 
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Figure 5: Size and distribution changes of hydrocortisone incorporated large unilamellar vesicles (LUVs) over 1 
hour in isotonic environment (top) and when subjected to hypertonic environment (bottom). LUVs were prepared 
in phosphate buffered saline (PBS) solution of 65 mOsm and exposed to buffer with tonicity of 65 (top) or 300 
mOsm (bottom), respectively. The dotted line marks 300 nm size (n=30) 
The changes in size distribution of HC-LUVs prepared in PBS65 where studied in isotonic 
environment (PBS65) and in hypertonic environment (PBS300) over a time period of 1 hour 
(Figure 5). When LUVs were exposed to isotonic environment (top graph), a single peak 
(approx. 290 nm) was observed. However, when LUV dispersions where exposed to hypertonic 
environment, a marked change in size distribution of the LUVs could be observed (bottom 
graph). The main peak that was observed in isotonic environment decreased in intensity when 
subjected to hypertonic environment. Additionally, a decreasing in sizes of LUVs could be 
observed. A general broader size distribution of LUVs sizes (i.e. higher polydispersity index) 
in hypertonic environment in comparison to the isotonic environment was measured. 
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5.3 Standard curves 
Standard curves measured with UV-vis spectroscopy were used in this work for the 
quantification of hydrocortisone and methylprednisolone. Calibration curves are based on the 
Beer-Lambert equation which relates absorbance is to the concentration of a compound in 
solution as reported by Equation 7 (Clark, 2017):  
Equation 7 𝐴 = 𝜀 ∗ 𝑙 ∗ 𝑐 
In this equation is 𝐴 the absorbance of the measured compound, e molar absorptivity, 𝑙 the 
width of the cuvette (1 cm standard) and 𝑐  the concentration of the compound in solution 
(Clark, 2017). 
 
Figure 6: Summary of hydrocortisone (HC) Standard curves plotted as absorbance over concentration (µM). Used 
to quantify amount of HC entrapped inside large unilamellar vesicles and amount permeated through cellulose 
hydrate and Permeapad® barrier (mean ± SD, n=36). 
As represented in Figure 6, the absorbance of hydrocortisone is plotted as a function of the drug 
concentration. R2 (correlation coefficient) was measured to be 0.9985 or above for the standard 
curves independently on what type of solvent was used. The R2 close to 1 indicated a linearity 
of the points on the curves. 
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Figure 7: Methylprednisolone (MP) standard curves (summary) plotted as absorbance over the standard 
concentrations used to quantify amount of MP entrapped inside large unilamellar vesicles and amount permeated 
through cellulose hydrate barrier (mean ± SD, n= ≥12). 
There were found a high correlation between the standard points with a R2 of 1 was found for 
methylprednisolone using 50% methanol/PBS (PBS300 or PBS65, respectively) as a solvent 
(Figure 7). 
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Figure 8: Standard curve of hydrocortisone (HC) for high performance liquid chromatography (HPLC) plotted as 
peak area under the curve over standard concentration (µM) employed to quantify HC entrapped inside 
Permeapad® barriers (mean ± SD, n=3). 
The standard curve of HC employed for quantification of HC entrapped inside Permeapad® 
when using HPLC. The R2 close to 1 shows that there is a linearity between the points on the 
standard curve (Figure 8). 
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5.4 Liposomal characterization 
The prepared LUVs were characterized according to diameter size, polydispersity, surface 
charge and drug entrapment. Results are shown in Table 8. 
Table 8: Large unilamellar vesicles (LUVs) diameter size (nm), polydispersity index (PDI), zeta potential (ZP) 
and drug entrapment efficiency into LUVs (EE) and the drug recovery of all the LUVs prepared in this study. The 
hydrocortisone or methylprednisolone incorporated LUVs were prepared in phosphate buffered saline (PBS) 
solutions of either 300 mOsm (PBS300) or 65 mOsm (PBS65) (mean ± SD, *n= ≥6, **n≥3). 
LUVs with drug 
(prepared in) 
Size 





275 ± 14 0.24 ± 0.02 - 2.78 ± 1.60 74 ± 3 97 ± 2 
Hydrocortisone 
(PBS65) 
300 ± 32 0.31 ± 0.08 - 5.86 ± 3.75 78 ± 2 98 ± 2 
Methylprednisolone 
(PBS300) 
268 ± 5 0.24 ± 0.01 - 1.29 ± 0.14 87 ± 1 96 ± 2 
Methylprednisolone 
(PBS65) 
285 ± 4 0.29 ± 0.03 - 3.12 ± 0.24 87 ± 0 96 ± 1 
 
The formulations of HC-LUVs and MP-LUVs showed smaller sizes and PDI for the LUVs 
prepared in PBS300 compared to PBS65. Additionally, a slightly more negative ZP was 
observed for LUVs prepared in PBS65 in comparison to PBS300. The amount of entrapped 
drug inside the LUVs determined by ultracentrifugation resulted in higher entrapment for the 
MP-LUVs (~87%), in comparison to HC-LUVs (~75%). 
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5.5 Thermodynamic solubility 
Due to difficulties in finding literature values that gave a good representation of the solubility 
of the studied drugs, the thermodynamic solubilities of both compounds in aqueous 
environment (PBS) were experimentally determined (see Table 9). 
Table 9: Measured thermodynamic solubilities of hydrocortisone and methylprednisolone in phosphate buffered 
saline (PBS) solutions of 300 mOsm (PBS300) and 65 mOsm (PBS65) (mean ± SD, *n=≥4). 
Buffer solution µM* mg/mL 
Hydrocortisone 
PBS300 1054 ± 29 0.382 ± 0.010 
PBS65 1033 ± 195 0.372 ± 0.077 
Methylprednisolone 
PBS300 254 ± 7 0.095 ± 0.003 
PBS65 262 ± 5 0.098 ± 0.002 
 
The thermodynamic solubility of hydrocortisone in PBS was measured to be 0.382 ± 0.010 
mg/mL for PBS300 and 0.372 ± 0.077 mg/mL for PBS65. The solubility for 
methylprednisolone in PBS was measured to be 0.095 ± 0.003 mg/mL for PBS300 and 0.098 ± 
0.002 mg/mL for PBS65. 
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5.6 In vitro drug permeability and release studies 
5.6.1 Drug permeability of saturated drug solutions through cellulose hydrate 
membranes 
Drug fluxes through cellulose hydrate membrane where measured employing saturated drug 
solutions prepared in PBS, and apparent permeability calculated (Equation 4 and Equation 5). 
Results are reported in Figure 9. 
 
Figure 9: Apparent permeability (Papp) of hydrocortisone (0.38 mg/mL*) and methylprednisolone (0.09 mg/mL*) 
from saturated solutions through cellulose hydrate barriers. Solutions were prepared in phosphate buffered saline 
(PBS) solutions of 300 mOsm (PBS300) or 65 mOsm (PBS65) (mean ± SD, n= 4, *thermodynamic solubility). 
The apparent permeability of HC in PBS300 through cellulose hydrate barriers was found to be 
4.41 ± 0.32 ‧ 10-5 cm/sec, and 5.19 ± 0.58 ‧ 10-5 cm/sec in PBS65. For MP in PBS300, the Papp 
was found to be 4.50 ± 0.68 ‧ 10-5 cm/sec and 4.91 ± 0.68 ‧ 10-5 cm/sec in PBS65. 
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5.6.2 Drug permeability and release studies cellulose hydrate membranes 
Permeability studies were conducted employing HC-LUV and MP-LUV formulations using 
cellulose hydrate membranes where changes in tonicity were induced. The apparent 
permeability of drug permeated from the solutions and LUVs plotted over the absolute osmotic 
pressures is depicted in Figure 10 (HC) and Figure 12 (MP). 
 
Figure 10: Correlation of absolute osmotic pressures (|πrel|) and apparent permeability (Papp) of hydrocortisone 
(HC) from large unilamellar vesicles (LUVs, 2 mM total concentration) through cellulose hydrate barriers. Data 
is compared to Papp of HC solutions (HC-SOLU, 0.38 mg/mL). HC-LUVs and HC-SOLU were prepared in 
phosphate buffered saline (PBS) of 300 mOsm (PBS300) or 65 mOsm (PBS65) in tonicity (mean ± SD, n=4, 
*p≤0.05). 
The apparent permeability of hydrocortisone through cellulose hydrate membranes were found 
to be more than two times higher and significantly different (*) for drug solutions compared to 
hydrocortisone incorporated LUVs in isotonic environments. For HC-LUVs prepared in 
PBS300, no significant change in permeability were found when LUVs were exposed to 
hypotonic environments. However, HC-LUVs prepared in PBS65 showed a significant 
difference in permeability (decreased) when LUVs were exposed to hypertonic environments 
(*) (Figure 10). 
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Cumulative µmole of drug released over time (Figure 11) were calculated using Equation 4 to 
establish at which time point during the studies a significant difference in the release profiles 
between isotonic LUVs compared to hypertonic LUVs could be found. 
 
Figure 11: Cumulative µmole of released drug (µmole) plotted over the time (hours) for hydrocortisone 
incorporated large unilamellar vesicles (HC-LUVs) prepared in phosphate buffered saline (PBS) solution with 
tonicity of 65 mOsm (PBS65). The LUVs were exposed to isotonic environment (PBS65) and hypertonic 
environment (buffer of 300 mOsm tonicity, PBS300). Line shows when significant difference between the release 
profiles occurred (mean ± 95% confidence interval, n=4). 
The cumulative amount of drug released (µmole) from HC-LUV65 through the cellulose 
hydrate barriers in isotonic environment (PBS65) and hypertonic environment (PBS300) 
showed a significant difference in the release profiles after 2.5 hours. 
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The apparent permeability for MP through cellulose hydrate barriers were plotted over the 
absolute osmotic pressure for MP in solution (MP-SOLU) and MP incorporated LUVs (Figure 
12). 
 
Figure 12: Correlation of absolute osmotic pressures (|πrel|) and apparent permeability (Papp) of 
methylprednisolone (MP) from large unilamellar vesicles (LUVs, 2 mM total concentration) through the cellulose 
hydrate barriers. Data is compared to Papp of MP solutions (MP-SOLU, 0.09 mg/ml). MP-LUVs or MP-SOLU 
were prepared in phosphate buffered saline (PBS) of 300 mOsm (PBS300) or 65 mOsm (PBS65) in tonicity (mean 
± SD, n=4, *p≤0.05). 
The apparent permeability of MP through cellulose hydrate membranes were found more than 
four times higher (significant different, *) for drug solutions than for MP-LUVs in isotonic 
environment. MP-LUVs prepared in PBS300 showed no clear significant change in 
permeability between isotonic and hypotonic environments, whereas MP-LUVs prepared in 
PBS65 showed a significant difference (*) in permeability when the LUVs were exposed to 
hypertonic environment (Figure 12) which were the same as for HC. 
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The cumulative amount of µmole drug released over time (Figure 13) was plotted to establish 
at which time point a significant difference between release profiles of drug released from MP-
LUVs exposed to hypertonic environment differed from isotonic environment. 
 
Figure 13: Cumulative amount of released drug (µmole) plotted over the time (hours) for methylprednisolone 
incorporated large unilamellar vesicles (MP-LUVs) prepared in phosphate buffered saline (PBS) solution with 
tonicity of 65 mOsm (PBS65). LUVs were exposed to isotonic environment (PBS65) and hypertonic environment 
(buffer of 300 mOsm tonicity, PBS300). Line shows when significant difference occurred (mean ± 95% confidence 
interval, n=4) 
The release curves showed that the cumulative amount of released drug (µmole) from MP-
LUV65 (Figure 13) was significant different between the isotonic environment and hypertonic 
environment after 1.5 hours. 
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5.6.3 Drug permeability and release studies using Permeapad® barriers 
The in vitro drug release of HC-LUVs was also studied employing the Permeapad® biomimetic 
barriers (to closer mimic biological membranes) The apparent permeability of HC-LUVs 
exposed to different tonicities are shown in Figure 14.  
 
Figure 14: Correlation of absolute osmotic pressures (|πrel|) and apparent permeability (Papp) of hydrocortisone 
(HC) from large unilamellar vesicles (LUVs, 2 mM total concentration) through the Permeapad® barriers. Data is 
compared to Papp of HC solutions (HC-SOLU, 0.38 mg/ml). HC-LUVs and HC-SOLU were prepared in phosphate 
buffered saline (PBS) of 300 mOsm (PBS300) or 65 mOsm (PBS65) in tonicity (mean ± SD, n=3, *p≤0.05) 
The apparent permeability of hydrocortisone through the Permeapad® barrier were found more 
than two times higher for drug solutions than for hydrocortisone incorporated LUVs (significant 
difference, *). HC-LUVs prepared in PBS300 showed a significantly different permeability 
when exposed to hypotonic environments (*). On the other hand, HC-LUVs prepared in PBS65 
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The cumulative amount of drug (µmole) released through the Permeapad® barriers were plotted 
over the time to establish at which time point a significant difference between the total amount 
of drug released from HC-LUVs exposed to hypotonic environment differed from isotonic 
environment. Results are depicted in Figure 15: 
 
Figure 15: Cumulative amount of released drug (µmole) plotted over the time (hours) for hydrocortisone 
incorporated large unilamellar vesicles (HC-LUVs) prepared in phosphate buffered saline (PBS) solution with 
tonicity of 300 mOsm (PBS300) used with the Permeapad® barriers. LUVs were exposed to isotonic environment 
(PBS300) and hypotonic environment (buffer of 65 mOsm tonicity, PBS65), (mean ± 95% confidence interval, 
n=3). 
The cumulative amount of drug (µmole) released from HC-LUV300 through the Permeapad® 
barriers in isotonic (PBS300) and hypotonic (PBS65) environments were evaluated using 95% 
confidence interval. There was not found any time point in which a significant difference in the 
release profiles of HCLUV300 were detected (Figure 15). 
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A preliminary study on the transfer of ions (changes in tonicity) from the acceptor chamber to 
the donor chamber of the Franz diffusion cells were conducted using cellulose hydrate 
membranes and the Permeapad® barriers. The acceptor chamber contained PBS300 (5 mL) with 
an initial tonicity of 304 mOsm (measured before the experiment) and the donor chamber 
contained distilled water (0.8 mL) with an initial tonicity of 2 mOsm. The donor chamber was 
sampled (150 µL) after 0.5, 1, 2, 3 and 4 hours and fresh distilled water (2 mOsm) were 
reintroduced. The samples from the donor chamber was measured using the Semi-Micro k-
7400 Osmometer (Knauer). Results are reported in Figure 16: 
 
Figure 16: Ion transfer of from acceptor chamber to donor chamber of the Franz cells using cellulose hydrate 
membranes and the Permeapad® barriers. Results are plotted as osmolality measured over the time (mean ± SD, 
n=2). 
The results show that the Permeapad® had a significantly lower rate of ions transferred across 
the barriers per time unit when compared to cellulose hydrate membranes.  
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6 Discussion 
6.1 Liposomal characterization 
The size distribution of LUVs prepared in PBS300 seems to be slightly lower than LUVs made 
in PBS65, the polydispersity of the measured LUV formulations gave the same trend with a 
slightly lower size distribution for LUVs prepared in PBS300. This could be attributed to the 
ionic content of the dispersing buffers where PBS300 have a higher ionic concentration than 
PBS65. Liposomal size and distribution have shown to be affected by the charge around them 
acting both on the electro static repulsion and sedimentation rate between the liposomes 
(Narenji et al., 2016). A higher ion concentration in the dispersing solution could contribute to 
more charges particles around the liposomal membranes which would enhance the electrostatic 
repulsions between individual liposomes reduce aggregation of the liposomal vesicles. 
The zeta potential (ZP) of the liposomal formulations where found to have slightly negative 
surface charges. LUVs prepared in PBS65 showed a slightly more negative ZP than for LUVs 
prepared in PBS300. The results seem consistent with previous findings of the same liposomal 
formulations (Wu et al., 2017). Carrión et al. (1994) showed that the ZP is affected by a number 
of variables such as the composition of the liposomal bilayer, the type and concentration of 
electrolytes in the dispersing buffer among others. A liposomal bilayer consisting of only 
phosphatidylcholine has shown to give a less charged surface (i.e. more neutral ZP) and a higher 
concentration of counter-ions in liposomal dispersions have shown to alter the surface charge 
of liposomes due to electrostatic charge shielding (Carrión et al., 1994; Coday et al., 2015; 
Sabín et al., 2006) This seems to be consistent with the findings of this study. 
The amount of entrapped drug inside the LUVs determined by ultracentrifugation, showed a 
higher entrapment of drug for MP-LUVs than for HC-LUVs. The higher entrapment of MP 
could be explained by the partition coefficient values of the two drugs incorporated into the 
liposomal formulations. LogP is the measurement of the partition coefficient, when adding 
drugs into a two-phase system like a liposomal dispersion a higher logP indicates that the drug 
prefers the lipid phase more than the aqueous phase. The logP value of MP = 1.80 (Grabowski 
et al., 2010) is higher than HC = 1.61 (Benet et al., 2011), this seem to give MP a higher degree 
of incorporation into the lipid bilayer than hydrocortisone which in turn could account for the 
higher entrapment of drug in inside the LUV formulation (Bozzuto and Molinari, 2015; 
Fatouros and Antimisiaris, 2002). 
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6.2 LUVs and tonicity  
The results shown in Figure 4 and Figure 5 confirm that the LUVs are susceptible to changes 
in the tonicity of the external environment of the liposomes. LUVs do shrink to a certain extent 
when exposed to hypertonic environment. This seems to be in accordance with literary findings 
on the subject (Abuin et al., 1995; Disalvo et al., 1996; Fujiwara and Yanagisawa, 2014; Wu 
et al., 2017). The lack of pronounced reduction in liposomal size can be attributed to the initial 
size of the liposomes themselves, GUVs have shown to be greatly affected by changes in 
tonicity and shrink to a higher degree than LUVs, and small unilamellar vesicles (SUVs) to be 
less affected by changes in tonicity to the extent of being osmotically insensitive (Hallett et al., 
1993; Johnson and Buttress, 1973; Polozov et al., 2001) The LUVs are possible too small in 
size to see real changes in size of the liposomes when subjected to hypertonic environment. 
When the LUVs were subjected to hypotonic environment there were observed a higher 
polydispersity and a shift in the LUVs size distribution towards a higher diameter size along 
with formation of new peaks, this would suggest that there is a limited swelling of the LUVs 
occurring. This seems consistent with previous findings for the same LUV dispersions (Wu et 
al., 2017).  
It should be noted that studies performed by changing the osmotic pressure of liposomes have 
shown that LUVs can undergo lysis if there is a great enough influx of water into the liposomes, 
i.e. changing the tonicity from isotonic to hypotonic environment (Ertel et al., 1993; Mui et al., 
1993; Ohno et al., 2009). LUVs have shown to not undergo lysis if there is an osmotic pressure 
small enough to induce size changes but not so high it would induce lysis (Hallett et al., 1993; 
Polozov et al., 2001). One of the studies where LUVs underwent lysis, used an osmotic 
differential of up to 2000 mOsm/kg to make the liposomal membrane stretch beyond its 
capabilities (Ohno et al., 2009). Whereas in this study the highest osmotic differential used 
were 235 mOsm/kg  
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6.3 Thermodynamic solubility 
The thermodynamic solubility measured for HC in PBS was compared to the literature values 
of 0.420 mg/mL in water (Benet et al., 2011). The results are consistent with previous findings 
of HC solubilized in a similar buffer solution (di Cagno and Luppi, 2013). The lower solubility 
of HC could be attributed to solutes already present in PBS300 and PBS65, the buffers which 
had an estimated phosphate concentration of 78 mM (PBS300) and 16 mM (PBS65) could have 
an impact on the solubility of drugs because the potential energy needed to the break bonds 
between water molecules and achieve solubilization is much lower for the phosphates (already 
solubilized) than for HC.  
The solubility for methylprednisolone was found to be 3-fold lower in PBS solutions than the 
reported measured value of 0.323 mg/mL in water (Benet et al., 2011). Some of the lower 
solubility could probably be attributed to the previously discussed reason of the presents of 
phosphates in the buffers used for solubilizing the drug. However, hydrocortisone did not show 
as much decrease in solubility. A possible explanation for the lower solubility of MP in 
comparison to HC could be attributed to differences in the molecular structure of MP. The 
molecular structure differs from HC by an extra methyl group on the second left hydrocarbon 
ring and an extra double bond on the far left of the molecule (Figure 2). Together the extra 
methyl group and double bond lowers the solubility of the molecule in water and could in turn 
lower the solubility in buffers further. This might be because of less hydrogen bonding 
capabilities on the far-left hydrocarbon ring coupled with the presence of already solubilized 
ion’s in the buffer solutions. The electronic potential left on the hydrocarbon ring for breaking 
hydrogen bonds might not be strong enough to break the hydrogen bonding between water 
molecules and water molecules to solutes. 
6.4 In vitro drug permeability and release studies 
6.4.1 Drug permeability studies of saturated drug solutions through cellulose 
hydrate membranes 
The apparent permeability between HC and MP dissolved in PBS solutions shown in Figure 9 
showed no significant differences in permeability. However, HC and MP showed a remarkably 
similar permeability through the cellulose hydrate membrane both in PBS300 and PBS65. This 
could be attributed to the drugs similar molecular weight and partition coefficients (Pade and 
Stavchansky, 1998). 
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6.4.2 Drug permeability and release studies using cellulose hydrate membranes 
The permeability of HC and MP solutions of through the cellulose hydrate membrane showed 
a significantly higher permeability than HC-LUV (two times higher) and MP-LUV (4 times 
higher) in isotonic environments (Figure 10 and Figure 12). This difference in permeability is 
probably due to the high entrapment of drug inside the liposomes which would lower the 
permeability of free drug through the cellulose hydrate membrane. The permeability of the drug 
solutions would be affected by the concentration gradient of drug through the cellulose hydrate 
membrane, but the permeability of drug from the liposomal formulations would be affected by 
the concentration gradient through the cellulose hydrate membrane and the liposomal 
membrane. The results seem consistent with previous findings on the difference in permeability 
between solutions of fluorescent makers and fluorescent makers entrapped in the same 
liposomal formulations as used in this study (Wu et al., 2017). 
The permeability of drug from HC-LUV showed a significantly lower permeability between 
HC-LUV65 in hypertonic environment (πrel 3 and 6 bar) compared to HC-LUV65 in isotonic 
environment (πrel 0 bar, Figure 10). For MP-LUV there were found a significantly lower 
difference for MP-LUV65 in hypertonic environment (πrel 6 bar) in comparison to MP-LUV65 
in isotonic environment (πrel 0 bar, Figure 12). The differences in permeability between the 
liposomes when subjected to hypertonic environment could be attributed to shrinkage of the 
liposomes in hypertonic environment. When the liposomes reduce in size the lipid bilayer 
would contract (i.e. become denser and shrink) hampering the diffusion of drugs out of the 
liposome. Results are consistent with previous findings of lipophilic markers entrapped inside 
the same liposomal formulations (Wu et al., 2017). There was no significant difference in 
permeability for either HC-LUVs or MP-LUVs in hypotonic environment compared to HC-
LUVs and MP-LUVs in isotonic environment (Figure 10 and Figure 12). This could mean that 
swelling of the LUVs is not as pronounced for lipophilic drugs with a high entrapment inside 
the liposomal bilayer as previously discussed in chapter 6.2. This seems consistent with 
previously findings for the permeability of lipophilic drugs with high entrapment inside of 
LUVs (Wu et al., 2017). A reason for the reduced swelling could be that lipophilic drugs 
trapped inside the liposomal membrane could reduce the liposomes ability to swell when 
exposed to a hypotonic environment similar to what cholesterol does (Mohammed et al., 2004).  
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The cumulative release curves of HC-LUV65 and MP-LUV65 in hypertonic environment (πrel 
6 bar) compared to isotonic environment (Figure 11 and Figure 13) showed that there were 
respectively 2.5 hours (HC-LUV65) and 1.5 hours (MP-LUV65) before a significant difference 
between the release of drug from the liposomal formulations occurred. The time before a 
significant difference in release were observed could be because drug is not automatically 
released from the LUVs, but changes in the concentration of drug in the liposomal dispersion 
could facilitate diffusion of drug out through the liposomal membrane because of difference in 
the concentration gradient. 
6.4.3 Drug permeability and release studies using Permeapad® barriers 
Permeapad® biomimetic barriers was employed as a method of trying to discern the relationship 
between the release of drug from liposomes through biological barriers. Hydrocortisone were 
selected as the drug used for these studies. Figure 14, shows a significantly higher permeability 
for HC in solutions compared to HC-LUVs in isotonic environment (approx. 3.5 times higher) 
which is consistent with previous findings for HC-SOLU vs. HC-LUVs where cellulose hydrate 
membranes were employed (chapter 5.6.1). The apparent permeability for HC-SOLU through 
the Permeapad® seems consistent with previous findings (di Cagno et al., 2015). The 
permeability of drug released from HCLUV300 in in hypotonic environment is shown to be 
significantly lower than HCLUV300 in isotonic environment and no significant difference 
between HC-LUV65 in hypertonic environment compared to HCLUV65 in isotonic 
environment (Figure 14). These results are different in comparison to what was found with 
cellulose barriers (chapter 5.6.1). This lead to an experiment comparing the ion transfer 
capabilities of the Permeapad® against the cellulose hydrate membranes. 
Initial experiments on the ion transfer capabilities of Permeapad® barrier compared to the 
cellulose hydrate barriers showed that ions transferred across the barriers where as much as 
two-fold lower for the Permeapad® during the experiments (Figure 16). This could mean that 
the transfer of ions is much slower when experiments are conducted with the Permeapad® and 
the tonicity changes around the liposomes happen at a slower rate than with the cellulose 
hydrate barriers. This wound then mean that the liposomes swell or contract at a slower rate 
than with the cellulose hydrate membrane.  
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Figure 15, shows that the release of drug seems to be lower (non-significant) for HC-LUV300 
in hypotonic environment after 2.5 hours and beyond. This could mean that the reduced changes 
in permeability between HC-LUV65 in hypertonic environment and HC-LUV65 in isotonic 
environment could be explained by the slow ion transfer of solute molecules between the donor 
chamber and acceptor chamber on the Franz cells and that the liposomes did not shrink. 
The drug recovery for all the studies done were 95-105% for the cellulose hydrate membranes 
and 90-100% for studies done with the Permeapad® barriers. The difference in recovery where 
analysed and there were found from 0-5% drug left on the cellulose hydrate barriers compared 
to 5-10% for the Permeapad® barriers. The higher amount of drug left on the Permeapad® 
barriers could be explained by the composition of the barriers relating to the cellulose hydrate 
membranes. 
7 Conclusions 
The results of this study demonstrate that LUVs were affected by changes in tonicity of the 
external environment around liposomes. The liposomes shrank when the external environment 
was changes from isotonic to hypertonic conditions, there were also observed a swelling of the 
LUVs when subjected to hypotonic conditions. The permeability of hydrocortisone and 
methylprednisolone incorporated LUVs through cellulose hydrate barriers were studied, there 
were found a significantly lower permeability for the drugs when subjected to hypertonic 
environment there were no significant differences found in hypotonic environment. It can then 
be concluded that the permeability of drugs incorporated into LUVs are affected by changes in 
tonicity in the external environment of a liposomal formulation. The permeability of 
hydrocortisone incorporated LUVs through the Permeapad® biomimetic barrier were studied, 
the findings were significant changes in the permeability of drug through the Permeapad® when 
subjected to hypotonic environment. There were Non-significant changes in permeability but 
because the exchange of ions through the Permeapad® where slower than for cellulose hydrate 
membranes the swelling/shrinking of LUVs where not as pronounced as for the cellulose 
hydrate.  
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8 Future perspectives 
The application of liposomes has showed great potential in the area of nasal drug delivery to 
the brain, to which osmotically active liposomes could be of great impact. The nasal pathways 
has the same tonicity as the body approx. 290 mOsm (Koeppen and Stanton, 2013). It has been 
shown that the nasal mucosa is susceptible to changes in tonicity, these changes by 
administering either hypertonic or hypotonic solutions to the nasal epithelium have shown to 
create shrinkage in the epithelial cells and by that reducing muco-ciliary clearance from the 
nasal pathways (Appasaheb et al., 2013; Min et al., 2001; Patel et al., 2017). This reduced 
clearance of the nasal mucosa would be beneficial for prolonging the time a drug formulation 
would stay in the same place and give the drug a chance to be released from the confines of the 
formulation. An additional way to ensure prolonged time for release of drug could be the 
addition of mucoadhesive properties to the liposomal formulation. The Permeapad® has 
previously shown great promise as a barrier mimicking biological membranes. To conclude 
that it is a viable option for studies based on the shrinking and swelling of liposomes, further 
studies and optimisation of the experimental procedures would be needed.  
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Liposomes are spherical vesicles consisting of a single or 
multiple phospholipid bilayers surrounding an aqueous 
core. Liposomes are appealing for drug delivery because of 
their role in solubilizing poorly water-soluble compounds 
(1, 2). Moreover, drugs incorporated into liposomes avoid 
early degradation and elimination, helping the improvement 
of their bioavailability profile. Previous studies have shown 
that uneven tonicity between the internal aqueous core and 
external environment of liposomes can influence the release 
of fluorescent markers from liposomes (3), however  this 
has not been proven yet for actual drugs. 
AIM 
To investigate if and to which extent the environmental 
tonicity perturbations (and osmotic pressure) affect the 
release profiles of hydrophilic (caffeine, CAF) and  
lipophilic (hydrocortisone, HC) drugs from large 
unilamellar vesicles (LUV). 
METHOD 
Preparation of PBS solutions with different tonicity 
A 74 mM phosphate buffer saline (PBS) solution 
(solution A) was prepared by dissolving 22.5 g 
NaH2PO4·H2O and 36.8 g Na2HPO4·2H2O in 5 L distilled 
water. The pH was adjusted to 7.40 with NaOH, whereas 
NaCl was employed to fix tonicity at 300 mOsm (Semi-
Micro Osmometer K-7400, Knauer, Berlin, Germany). 
Solution A was diluted with distilled water to obtain two 
other solutions (B and C, Table 1) with lower tonicities. 
Solution pH Tonicity (mOsm) 
A 7.39 ± 0.02 297 ± 15 
B 7.50 ± 0.04 183 ± 1 
C 7.60 ± 0.05 64 ± 4 
Table 1: The PBS solutions used. 
Preparation of LUV 
LUV were prepared following a method previously 
described by Wu et al. (3). In brief, an organic mixture of 
phosphatidylcholine, methanol, chloroform and PBS was 
prepared. Organic solvents were gently evaporated by 
rotary evaporation (Büchi R-124 rotavapor, Büchi vacuum 
pump V-500, Büchi B-480 water bath, Büchi Labortechnik 
AG, Flawil, Switzerland), and the obtained liposomal 
dispersion was extruded at room temperature (23 – 25 °C) 
through polycarbonate membrane filters (lowest pore-size 
400 nm, Nuclepore Track-Etched Membranes, Whatman 
International Ltd., Buckinghamshire, UK). For loading the 
drugs in liposomes, caffeine was dissolved in the PBS, 
whereas hydrocortisone was dissolved in the organic phase 
together with lipid. For both drugs, LUV dispersions were 
prepared using solution A (300 mOsm) or, alternatively, 
solution C (65 mOsm). 
Characterization of LUV 
Liposomal sizes were determined by photon correlation 
spectroscopy, and surface charges of liposomes were 
determined by zeta potential measurement (Zetasizer Nano 
Zen 2600, Malvern, Worcestershire, UK). 
Ultracentrifugation method (3) was employed to quantify 
liposomal drug loading. 
In vitro drug release study 
Drug release studies were performed employing Franz 
diffusion cells (standard 0.64 cm2 diffusional area jacketed 
flat ground joint, PermeGear Ink, Hellertown, USA) 
equipped with cellulose hydrate membrane (Visking 
dialysis tubing MWCO 12 – 14 kDa, Medicell). 
Experiments were performed at 35 °C (Julabo F12-ED, 
Julabo Laboratechnik, Seelback, Germany) over a period of 
4 hours (n = 4). The acceptor chamber was filled with 
different PBS solutions (Table 1) with different ion 
strengths and tonicities. At time zero, LUV dispersion 
(0.8 mL) containing caffeine (or, alternatively, 
hydrocortisone (2 mM total drug concentration) was 
applied to the donor chamber. The drug concentration in the 
acceptor chamber was detected by UV-visible spectroscopy 
(Costar® UV 96-well plate, Corning, New York, USA) at 
wavelengths 273 nm for caffeine and 247 nm for 
hydrocortisone. The flux of each drug through the cellulose 
hydrate membrane (J) was determined from Equation 1: 
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(1) 
where dm/dt represents the variation of mass over time and 
A is the diffusional area. The relative osmotic pressure ( rel) 
was estimated by Equation 2: 
 (2) 
Where R represents the gas constant, T is the absolute 
temperature and Osm(out)-Osm(in) is the difference between 
external and internal osmolality (units of mOsm) of LUV. 
Based on Equation 2, a negative osmotic pressure is 
produced when water influx into LUV (Osm(out)<Osm(in)) 
and positive relative osmotic pressure when water efflux 
out of LUV (Osm(out)>Osm(in)). 
RESULTS AND DISCUSSION 
Characterization of LUV 
The general characteristics of the LUV dispersions are 
reported in Table 2. 








Empty 65 298 ± 11 -4.6 ± 0.3  
300 246 ± 13 -0.7 ± 0.3  
Caffeine 
65 333 ± 33 -6.6 ± 1.0 26 ± 0 
300 279 ± 5 -0.2 ± 0.0 22 ± 1 
Hydro-
cortisone 
65 280 ± 24 -9.4 ± 0.5 79 ± 1 
300 281 ± 4 -1.3 ± 0.2 71 ± 1 
Table 2: General characteristics of LUV prepared in PBS at 
different tonicity. 
All formulations had a uniform size and surface charge, 
with some small differences related to the ionic 
composition of the buffer in which they were dispersed.. 
LUV were slightly negatively charged in 65 mOsm buffer, 
and became more neutral at increased ion strength. Drug 
entrapment was approximately 4-fold times higher for the 
hydrocortisone-LUV in comparison to caffeine-LUV. 
In vitro drug release study 
In Figure 1 the correlation between the relative osmotic 
pressure (generated by uneven tonicity between inner core 
and external environment of LUV) is plotted against the 
measured fluxes of caffeine (A) and hydrocortisone (B). As 
it can be observed in Figure 1, both drugs are highly 
influenced by a positive osmotic pressure. Specifically, 
when negative osmotic pressure is applied 
(Osm(out)<Osm(in)), the flux of water (chemical activity 
driven) is directed inwards, against the direction of the drug 
molecules. In this case, a small inflection in flux could be 
observed at the most negative osmotic pressure (i.e. highest 
inwards flow of water) for both CAF and HC., When 
positive osmotic pressure was applied (Osm(out)>Osm(in), 
flux of water directed outwards from LUV), a significant 
decrease of drug release was observed for both dugs. This 
interesting phenomenon can be explained by LUV 
shrinkage that alters the phospholipid bilayer density and 
rigidity, increasing its resistivity to permeation and 
therefore reducing drug release. This phenomenon seems to 
affect hydrophilic compounds (such as CAF) to a higher 
extent than lipophilic compounds (i.e. HC) that are 
embedded in the phospholipid bilayer. 
 
Figure 1: Correlation between the relative osmotic pressure 
(generated by different tonicities between inner core and 
external environment of vesicles) and the observed fluxes of 
caffeine (A) and hydrocortisone (B) in LUV dispersion 
(* p ≤ 0.05). 
CONCLUSION 
Perturbation of environmental tonicity seems to play a 
fundamental role in the release of caffeine and, to a minor 
extent, hydrocortisone from LUV. This phenomenon could 
be of crucial importance when designing drug nanocarriers 
with optimal controlled release properties. 
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